- Home
- SNFCA vs TSHA Comparison
SNFCA vs TSHA Comparison
Compare SNFCA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNFCA | TSHA |
|---|---|---|
| Founded | 1965 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.1M | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNFCA | TSHA |
|---|---|---|
| Price | $9.23 | $5.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | 31.8K | ★ 3.4M |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $340,876,482.00 | $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.19 | ★ N/A |
| Revenue Growth | ★ 3.25 | N/A |
| 52 Week Low | $7.32 | $1.05 |
| 52 Week High | $12.83 | $5.95 |
Technical Indicators
Market Signals| Indicator | SNFCA | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 72.54 | 66.31 |
| Support Level | $8.52 | $5.22 |
| Resistance Level | $8.82 | $5.54 |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | 0.08 | 0.13 |
| Stochastic Oscillator | 100.00 | 89.84 |
Price Performance
Historical ComparisonAbout SNFCA Security National Financial Corporation
Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.